TY - JOUR
T1 - Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
AU - Towns, Clodagh
AU - Richer, Madeleine
AU - Jasaityte, Simona
AU - Stafford, Eleanor J.
AU - Joubert, Julie
AU - Antar, Tarek
AU - Martinez-Carrasco, Alejandro
AU - Makarious, Mary B.
AU - Casey, Bradford
AU - Vitale, Dan
AU - Levine, Kristin
AU - Leonard, Hampton
AU - Pantazis, Caroline B.
AU - Screven, Laurel A.
AU - Hernandez, Dena G.
AU - Wegel, Claire E.
AU - Solle, Justin
AU - Nalls, Mike A.
AU - Blauwendraat, Cornelis
AU - Singleton, Andrew B.
AU - Tan, Manuela M.X.
AU - Iwaki, Hirotaka
AU - Morris, Huw R.
AU - Gatto, Emilia M.
AU - Kauffman, Marcelo
AU - Khachatryan, Samson
AU - Tavadyan, Zaruhi
AU - Shepherd, Claire E.
AU - Hunter, Julie
AU - Kumar, Kishore
AU - Ellis, Melina
AU - Rentería, Miguel E.
AU - Koks, Sulev
AU - Zimprich, Alexander
AU - Schumacher-Schuh, Artur F.
AU - Rieder, Carlos
AU - Awad, Paula Saffie
AU - Tumas, Vitor
AU - Camargos, Sarah
AU - Fon, Edward A.
AU - Monchi, Oury
AU - Fon, Ted
AU - Galleguillos, Benjamin Pizarro
AU - Miranda, Marcelo
AU - Bustamante, Maria Leonor
AU - Olguin, Patricio
AU - Chana, Pedro
AU - Tang, Beisha
AU - Shang, Huifang
AU - Krüger, Rejko
AU - Global Parkinson’s Genetics Program (GP2)
AU - Morris, Huw R.
N1 - Funding Information:
This research is supported by the Aligning Science Across Parkinson’s Initiative, the Intramural Research Program, National Institute on Aging, National Institutes of Health, Department of Health and Human Services, project ZO1 AG000949, and the Michael J. Fox Foundation for Parkinson’s Research. Data used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research ( https://gp2.org ). For a complete list of GP2 members see https://gp2.org .
Funding Information:
A.B.S. and C.B. are supported by the Intramural Research Program of the National Institute on Aging and have received grant support from the Michael J. Fox Foundation for Parkinson’s Research and the Aligning Science Across Parkinson’s Initiative. A.B.S. has received royalty payments related to a diagnostic for stroke. A.B.S. is an editor for npj Parkinson’s Disease. A.B.S. was not involved in the journal’s review of, or decisions related to, this manuscript. H.L., H.I., D.V., K.L., and M.A.N. are consultants employed by Data Tecnica International. Data Tecnica is engaged in a consulting agreement with the US National Institutes of Health. H.R.M. is employed by UCL. In the last 24 months, he reports paid consultancy from Biogen, Biohaven, Lundbeck; lecture fees/honoraria from Wellcome Trust, Movement Disorders Society; Research Grants from Parkinson’s UK, Cure Parkinson’s Trust, PSP Association, CBD Solutions, Drake Foundation, Medical Research Council, Michael J. Fox Foundation. H.R.M. is also a co-applicant on a patent application related to C9ORF72—Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). BC and JS are employed by the Michael J. Fox Foundation for Parkinson’s Research. All other authors declare no financial or non-financial competing interests.
Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/9/12
Y1 - 2023/9/12
N2 - The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia.
AB - The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia.
UR - http://www.scopus.com/inward/record.url?scp=85170643330&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/37699923
U2 - 10.1038/s41531-023-00533-w
DO - 10.1038/s41531-023-00533-w
M3 - Article
C2 - 37699923
AN - SCOPUS:85170643330
SN - 2373-8057
VL - 9
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
IS - 1
M1 - 131
ER -